Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer

Johnson & Johnson (JNJ) reported that a new study of its ERLEADA® (apalutamide) treatment, combined with androgen deprivation therapy (ADT), reduced the risk of recurrence or death by 62% in high-risk prostate cancer patients compared to surgery alone. The study also showed a 51% lower risk of metastasis or death. Results were presented at the ESMO Congress 2026.

Johnson & Johnson's study found that apalutamide plus ADT reduced the risk of metastasis or death by 51% compared to surgery alone in high-risk prostate cancer patients. At three years, 63% of patients on the regimen remained event-free versus 41.4% with surgery. The substudy involved 408 patients and was presented at ESMO Congress 2026.

Johnson & Johnson reported that its experimental prostate cancer drug, acquired via its $3.05B Halda Therapeutics deal, showed tumor shrinkage in an early-stage trial.

Johnson & Johnson (JNJ) reported that its experimental prostate cancer drug, JNJ-6143, showed promising results in an early-stage trial. Among 31 patients, 77% saw PSA reductions of at least 50%. The drug was acquired via JNJ's $3.05B purchase of Halda Therapeutics. Further testing is needed to confirm long-term effectiveness and safety.

Johnson & Johnson reported positive early-stage trial results for its prostate cancer drug JNJ-6143, acquired via a $3.05B deal. In 31 patients, 77% saw PSA levels drop by 50%+, with 69% showing tumor shrinkage. Side effects included nausea and elevated cholesterol. Data was presented at the European Society for Medical Oncology Congress.

Johnson & Johnson (JNJ) and Smith & Nephew (SN) ended merger talks over leadership disputes. J&J's orthopaedics unit, valued at up to $22B, may instead be spun off. J&J shares fell 1.42% on the news. The spin is expected in mid-2027, with a pro forma to be released on December 8.